Research Papers:
Characteristics of Chinese herbal medicine usage in ischemic heart disease patients among type 2 diabetes and their protection against hydrogen peroxide-mediated apoptosis in H9C2 cardiomyoblasts
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2333 views | HTML 9355 views | ?
Abstract
Fuu-Jen Tsai1,2,3,*, Tsung-Jung Ho1,4,5,*, Chi-Fung Cheng6, Yi-Tzone Shiao7, Wen-Kuei Chien8, Jin-Hua Chen8,9, Xiang Liu10, Hsinyi Tsang10, Ting-Hsu Lin2, Chiu-Chu Liao2, Shao-Mei Huang2, Ju-Pi Li1,11, Cheng-Wen Lin12, Jaung-Geng Lin1, Yu-Ching Lan13, Yu-Huei Liu2,14, Chien-Hui Hung15, Jung-Chun Lin16, Chih-Chien Lin17, Chih-Ho Lai18, Wen-Miin Liang6, Ying-Ju Lin1,2
1School of Chinese Medicine, China Medical University, Taichung, Taiwan
2Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
3Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan
4Division of Chinese Medicine, China Medical University Beigang Hospital, Yunlin County, Taiwan
5Division of Chinese Medicine, Tainan Municipal An-Nan Hospital-China Medical University, Tainan, Taiwan
6Graduate Institute of Biostatistics, School of Public Health, China Medical University, Taichung, Taiwan
7Heart Center, China Medical University Hospital, Taichung, Taiwan
8Biostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan
9School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
10National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
11Rheumatism Research Center, China Medical University Hospital, Taichung, Taiwan
12Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan
13Department of Health Risk Management, China Medical University, Taichung, Taiwan
14Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
15Graduate Institute of Clinical Medical Science, Chang-Gung University, Taipei, Taiwan
16School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
17Department of Cosmetic Science, Providence University, Taichung, Taiwan
18Department of Microbiology and Immunology, Chang Gung University, Taoyuan, Taiwan
*These authors have contributed equally to this work
Correspondence to:
Ying-Ju Lin, email: [email protected]
Wen-Miin Liang, email: [email protected]
Keywords: type 2 diabetes, ischemic heart disease, Chinese herbal medicine, oxidative stress, cardiomyoblasts
Received: June 01, 2016 Accepted: December 27, 2016 Published: January 14, 2017
ABSTRACT
Evidence for long-term use of Chinese herbal medicine (CHM) as an adjuvant treatment in patients with type 2 diabetes (T2D) remains limited. This study aimed to assess the frequency of use, utilization patterns, and therapeutic effects of adjuvant CHM for ischemic heart disease (IHD) in patients with T2D in Taiwan. We identified 4620 IHD patients with T2D. After matching for age, gender, and insulin use, 988 subjects each were allocated to a CHM group and a non-CHM group. There were no differences in baseline characteristics except for comorbidities. The CHM group contained more cases with chronic obstructive pulmonary disease, hepatitis, ulcer disease, and hyperlipidemia. The cumulative survival probability was higher in CHM users than in matched non-CHM users aged 60 years or older (P < .0001, log rank test) regardless of gender (P = .0046 for men, P = .0010 for women, log rank test). Among the top 12 CHM combinations, Shu-Jing-Huo-Xue-Tang and Shao-Yao-Gan-Cao-Tang (13.6%) were the most common. This dual combination improved antiapoptotic activity in H2O2-exposed H9C2 cells by enhancing phosphorylation of glycogen synthase kinase-3β and p38 mitogen-activated protein kinase and could increase the survival of myocardial cells. Our study suggests that adjuvant CHM therapy may increase the survival probability and provides a comprehensive list for future investigations of the safety and efficacy of CHM for IHD patients with T2D.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14657